Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal conjugate vaccine 13-GlaxoSmithKline-chickenpox
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
pneumococcal conjugate vaccine 13-GlaxoSmithKline-chickenpox refers to the co-administration of a 13-valent pneumococcal conjugate vaccine (PCV13) and GlaxoSmithKline's investigational live-attenuated varicella vaccine (GSK2761411A). This combination is primarily evaluated in Phase 3 pediatric clinical trials (such as NCT05583331) to assess the safety and immunogenicity of GSK's intramuscular varicella vaccine when given alongside other routine childhood immunizations. The varicella component is a live-attenuated virus (Oka strain) intended to prevent chickenpox (varicella), while the PCV13 component provides protection against 13 serotypes of Streptococcus pneumoniae, the causative agent of pneumonia, meningitis, and bacteremia. The investigational varicella vaccine is specifically designed for intramuscular injection, providing a potential alternative to the traditional subcutaneous route used for marketed varicella vaccines.
- Other names
- PCV13 + GSK varicella vaccinepneumococcal conjugate vaccine 13 + varicella vaccine (GlaxoSmithKline)
Beyond the preview
Go deeper on pneumococcal conjugate vaccine 13-GlaxoSmithKline-chickenpox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal conjugate vaccine 13-GlaxoSmithKline-chickenpox.